Morphological Biomarkers Related to Visual Acuity in Patients With Radiation Retinopathy Treated With Intravitreal Ranibizumab

BACKGROUND AND OBJECTIVE: Our objective was to monitor variables via spectral-domain optical coherence tomography (SD-OCT) and identify the most relevant biomarkers related to best-corrected visual acuity (BCVA) in radiation retinopathy (RR)

Détails bibliographiques
Publié dans:Ophthalmic surgery, lasers & imaging retina. - 2013. - 55(2024), 5 vom: 01. Mai, Seite 255-262
Auteur principal: Corona, Stephanie Trejo (Auteur)
Autres auteurs: Ali, Omar I, Yu, Hannah J, Schefler, Amy C, RRR Study Group
Format: Article en ligne
Langue:English
Publié: 2024
Accès à la collection:Ophthalmic surgery, lasers & imaging retina
Sujets:Clinical Trial, Phase II Journal Article Multicenter Study Randomized Controlled Trial Angiogenesis Inhibitors Biomarkers Ranibizumab ZL1R02VT79 Vascular Endothelial Growth Factor A
LEADER 01000caa a22002652c 4500
001 NLM368981797
003 DE-627
005 20250305205316.0
007 cr uuu---uuuuu
008 240229s2024 xx |||||o 00| ||eng c
024 7 |a 10.3928/23258160-20240129-01  |2 doi 
028 5 2 |a pubmed25n1229.xml 
035 |a (DE-627)NLM368981797 
035 |a (NLM)38408221 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Corona, Stephanie Trejo  |e verfasserin  |4 aut 
245 1 0 |a Morphological Biomarkers Related to Visual Acuity in Patients With Radiation Retinopathy Treated With Intravitreal Ranibizumab 
264 1 |c 2024 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 16.05.2024 
500 |a Date Revised 17.07.2024 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a BACKGROUND AND OBJECTIVE: Our objective was to monitor variables via spectral-domain optical coherence tomography (SD-OCT) and identify the most relevant biomarkers related to best-corrected visual acuity (BCVA) in radiation retinopathy (RR) 
520 |a PATIENTS AND METHODS: A post-hoc analysis of the two-year Ranibizumab for Radiation Retinopathy (RRR) trial analyzed vision and OCT parameters including intraretinal fluid, ellipsoid zone (EZ) disruption, retinal pigment epithelium atrophy, hard exudates, retinal hemorrhage, retinal neovascularization, and subfoveal fluid. BCVA and SD-OCT parameters were evaluated by univariate analysis and a mixed-effects model 
520 |a RESULTS: Forty eyes from the RRR trial were included. Intraretinal cyst vertical size (week 24: P = 0.032; week 48: P = 0.021), neovascularization (week 48: P = 0.028; week 72: P = 0.025), and EZ disruption (week 72: P = 0.029; week 104: P = 0.019) were the clinical parameters most relevant to BCVA by univariate analysis in at least two time points. The mixed-effects model confirmed the relevance of intraretinal cyst vertical size (P = 0.001) and neovascularization (P = 0.001) but not EZ disruption (P = 0.119) over the course of the study 
520 |a CONCLUSIONS: This study characterizes the course of visual loss in RR by identifying intraretinal cyst vertical size, neovascularization, and EZ disruption as biomarkers of poor BCVA over a span of two years. Larger multicenter studies are needed to confirm these findings. [Ophthalmic Surg Lasers Imaging Retina 2024;55:255-262.] 
650 4 |a Clinical Trial, Phase II 
650 4 |a Journal Article 
650 4 |a Multicenter Study 
650 4 |a Randomized Controlled Trial 
650 7 |a Angiogenesis Inhibitors  |2 NLM 
650 7 |a Biomarkers  |2 NLM 
650 7 |a Ranibizumab  |2 NLM 
650 7 |a ZL1R02VT79  |2 NLM 
650 7 |a Vascular Endothelial Growth Factor A  |2 NLM 
700 1 |a Ali, Omar I  |e verfasserin  |4 aut 
700 1 |a Yu, Hannah J  |e verfasserin  |4 aut 
700 1 |a Schefler, Amy C  |e verfasserin  |4 aut 
700 0 |a RRR Study Group  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Ophthalmic surgery, lasers & imaging retina  |d 2013  |g 55(2024), 5 vom: 01. Mai, Seite 255-262  |w (DE-627)NLM224956647  |x 2325-8179  |7 nnas 
773 1 8 |g volume:55  |g year:2024  |g number:5  |g day:01  |g month:05  |g pages:255-262 
856 4 0 |u http://dx.doi.org/10.3928/23258160-20240129-01  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_40 
912 |a GBV_ILN_63 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_90 
912 |a GBV_ILN_91 
912 |a GBV_ILN_130 
912 |a GBV_ILN_135 
912 |a GBV_ILN_136 
912 |a GBV_ILN_151 
912 |a GBV_ILN_181 
912 |a GBV_ILN_203 
912 |a GBV_ILN_217 
912 |a GBV_ILN_235 
912 |a GBV_ILN_289 
912 |a GBV_ILN_294 
912 |a GBV_ILN_297 
912 |a GBV_ILN_350 
912 |a GBV_ILN_352 
912 |a GBV_ILN_674 
912 |a GBV_ILN_676 
912 |a GBV_ILN_688 
912 |a GBV_ILN_698 
912 |a GBV_ILN_721 
912 |a GBV_ILN_737 
912 |a GBV_ILN_791 
912 |a GBV_ILN_812 
951 |a AR 
952 |d 55  |j 2024  |e 5  |b 01  |c 05  |h 255-262